Eye Institute seminar series continues
to appeal to NZ optometrists
Eye Institute held another successful
seminar as part of its 2009 Education
Series recently, with more than 150
optometrists and final year students
attending from all over the country. Eye Institute
was very appreciative of the support from Alcon,
who were sponsors for this seminar.
Attendees were divided into three rooms
with Eye Institute’s doctors rotating between
the rooms, presenting their sessions covering
diagnostic and therapeutics in everyday
practice and the latest advances in shared-care
management in New Zealand.
Dr Trevor Gray presented a number of case
studies that addressed issues optometrists may
come across in the therapeutic co-management
of refractive surgery patients. Central to his
presentation was the way in which epithelium
healing progresses.
“By explaining to a patient how the epithelium
heals you can prepare them with what to
expect through that process,” said Dr Gray. “If
they understand, they’ll be less likely to be
unhappy or disappointed with their resultant
vision. Emphasis should be placed on the point
that every 2 days, a normal healing epithelium
becomes clearer and smoother, resulting in
better vision.”
Professor Charles McGhee continued
with a look at evidence based results for
the increasingly high-profile technique of
riboflavin collagen cross-linking (CXL) in
keratoconus. Using the outline of an invited
paper he presented to the European Society of
Ophthalmology (SOE) in June he highlighted
both the limited long term data and the lack
of alternative minimally invasive treatments
that treat the underlying corneal changes in
progressive keratoconus.
“There are various levels of dependable
evidence and unfortunately for clinical
studies of CXL in keratoconus the quality of
studies are extremely variable and difficult to
easily interpret,” explains Professor McGhee.
“However, one of the best studies at the moment
is the Melbourne study, a randomised controlled
trial of CXL in progressive keratoconus,
whose preliminary results suggest a genuine
stabilisation of corneal steepening in almost all
treated eyes after CXL.”
The possible complications were also outlined
but as Prof McGhee stated serious complications
of CXL are uncommon and the alternative for
more than 20% of sufferers is progression to
a corneal transplant during the course of the
disease.
“The ideal patient is the younger, progressing
keratoconic,” said Prof McGhee. “Not so much
the 40-50 year old who is stable and doing well
with their contact lenses. Indeed, Charlotte
Jordan and I have now treated a number of early
keratoconics, typically in their late teens or early
twenties, with a view to keeping them in contact
lenses and preventing progression to corneal
transplantation. If I were a keratoconic today,
and my cornea was steepening by a dioptre
or more per year, having carefully studied the
evidence base and looked at the early results of
our Auckland Study, I would certainly consider
CXL as a treatment option.”
In summary, Prof McGhee concluded that
there were few prospective studies and with
more than 20,000 patients treated, fewer than
400 eyes have actually been reported on for
more than 12 months follow-up. Nonetheless,
it has generally been shown to be clinically safe
and effective in the short term with visually
significant complication rates typically being
less than 2-3%, but very long term consequences
of CXL are unknown at this stage. Overall, CXL
generally appears to be effective in halting
keratoconus progression in appropriately
selected cases, and some patients have a modest
degree of keratoconus reversal.
Dr Gray’s second presentation looked at
the improved LASIK and corneal transplant
outcomes offered by New Zealand’s latest
IntraLase Femtosecond (iFS) laser that Eye
Institute has been working with for a few
months.
“Emerging applications for the iFS include
corneal transplants, astigmatic keratotomies
and iLASIK flap advances,” said Dr Gray. “The iFS
has a number of advantages over the previous
4th generation IntraLase for LASIK, such as a
reduction in flap creation from 30 to less than
10 seconds, making the process quicker and
safer with very short suction times on the eye.
Also, for those particularly with astigmatism
and hyperopia, an oval shaped flap can be made
to match an oval shaped cornea, and finally the
‘bevel-in’ cut edge of the flap provides for greater
flap strength and stability.”

Continuing with some more case studies
Professor Helen Danesh-Meyer covered key
points that attendees wouldn’t want to miss
when assessing patients in regards to neuroophthalmic
presentations, including an overview
of Horners syndrome.
“There are four important considerations to
make when treating a patient who has presented
with a visual/headache complaint,” explains Prof
Danesh-Meyer. “These are life threatening and
definitely things you don’t want to miss. They
include, angle closure, pituitary apoplexy, GCA or
aneurism.”
Prof Danesh-Meyer also gave some questions
that can be posed to the patient as a means of
providing clues as to the possible diagnosis.
Within her presentation she outlined the key
features of Horners syndrome; ptosis, miosis,
hydrosis, upside down ptosis and dilation lag
and the four signs for it. Classically, cocaine eye
drops are used to diagnose Horner’s syndrome.
However, because they are not readily available,
apraclonidine is a useful alternative. One drop
of apraclonidine in both eyes will eliminate
the anisocoria by resulting in dilation of the
Horner’s pupil.
Dr Tony Morris covered the role of patient
psychology in a practice’s success. He explained
how the patient’s perception of their connection
with their optometrist can significantly influence
their sense of satisfaction, and that their
emotions can impact not only their decision
making but their perception of their health care
professional, the service supplied, the outcome,
and the resultant expression of that perception
to not only the professional involved but also others.
Emotions can also affect a patient’s ability to cope
with issues that may arise along the patient care
path and their subsequent response to an optometrist’s
reassurance in regards to these issues.
“There are four essential core qualities that patients
want,” explains Dr Morris. “Communication, access, interpersonal skills and
coordination and follow-up care. In today’s healthcare
environment the technical skills of a health professional
in a good practice are taken for granted, there is no longer
a point of difference based on this. A positive point of
difference now comes with the level of service that a
practice can provide.”
In Professor Danesh-Meyer’s second presentation she
looked at the management of ocular hypertension with a case
study of a 34 year old lawyer with recurrent irritation from
contact lenses and a noted elevated RE pressure. This
case highlighted the points to consider when presented
with asymmetric IOP, namely, trauma, anterior segment
inflammation, angle closure, pigment dispersion and
pseudoexfoliation or carotidcavernous fistula.
The topical treatment for posterior disease was the next
session with Dr Peter Hadden outlining the causes, risk
factors and treatment options for cystoid macular oedema. Dr
Hadden also expanded on the possible causes and treatment
options for raised intraocular pressure in an inflamed eye
and the relationship between this and steroids and how
topical, inhaled or systemic steroids can cause it.
“Systemic steroids in renal transplant patients causes a
rise in IOP in 10% of cases,” said Dr Hadden. “Optometrists
should look towards working with GP’s in these cases and
checking these patients IOP’s.”
Dr Adam Watson’s overview of contact lens related
corneal epitheliopathy and its management provided
attendees with some common and less common forms of
epitheliopathy, followed by a closer look at the
uncommon ones, tips on how to identify them and their
treatment.
“The less common forms of contact lens associated
epitheliopathy, hurricane keratopathy and limbal
stem cell dysfunction epitheliopathy’s have in
common a ‘whorling’ pattern of punctuate staining and
variable presence of epithelial microcycsts,” he said.
“The whorling is an exaggerated pattern of normal
epithelial migration that becomes more apparent when
epithelial turnover increases or in limbal stem cell
dysfunction.”
Dr Watson explained that the aetiology of limbal
stem cell dysfunction, and eventual failure, probably
lies in a chronic insult to the limbal stem cells causing
inflammation and stem cell death. Probable causes may
include hypoxia, chronic inflammation and chemical
injury.
“Treatment involves removing the stimulus
for damage, suppressing inflammation and creating a
supportive environment for recovery of function. This may
include no contact lens wear, consideration of infection as
a possibility, the avoidance of preservatives when possible,
removal of unnecessary topical medications, use of
non-preserved lubricants, non-preserved steroids and
doxycycline, appropriate lid hygiene, Botox-induced ptosis
or tarsorrhaphy, amniotic membrane transplant or
limbal stem cell transplant if permanent or disabling
damage.
“It is important to note also that recovery is slow and
may take months.”
More commonly seen, and less severe is contact
lens related microcystic epitheliopathy that has a
similar aetiology but without stem cell injury. Recovery is
also prolonged, relying on the turnover of epithelium to
restore a healthy cornea with consequent improvement
in vision and the principles of treatment are the same.
Return to contact lens wear should be with close review
for further epitheliopathy, and strategies to reduce the
likelihood of future injury such as decreasing wear time,
daily disposables or ceasing contact lens wear should be
considered.
The final session was a clinical quiz conducted
by Dr Peter Ring that discussed patient cases and
subsequent treatment for the following conditions;
Hydroxychloroquine (Plaquenil toxicity), Amiodarone toxicity,
Idiopathic Intracranial Hypertension, and examples
of the difference between dermatochalasis and
blepharachalasis, along with examples of Buphthalmos
(Ox eye) and epiblepharon, entropian and trichiasis
euryblepharon.
Eye Institute’s clinical conference is being held
November 1 at the Owen G Glenn Building, University
of Auckland Business School and will feature, amongst Eye
Institute’s doctors, keynote speaker Associate Professor
Gerard Sutton.
|